# US 2013/0280816 A1 · ApoIII and the Treatment and Diagnosis of Diabetes

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0280816 A1
- Document ID: US20130280816A1
- Status: Published application
- Kind: A1
- Application number: 13/935,825
- Filed: 2013-07-05
- Published: 2013-10-24
- Earliest claimed: 2003-04-29
- Assignees: BioCrine AB
- Applicants: Biocrine AB
- Inventors: Per-Olof Berggren
- Web page: https://patentgrep.com/patent/US20130280816A1

## CPC

- G01N 33/92: involving lipids, e.g. cholesterol {, lipoproteins, or their receptors (steroid hormones G01N33/743)}
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- C07K 16/18: against material from animals or humans
- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- G01N 30/02: Column chromatography
- G01N 33/5041: {involving analysis of members of signalling pathways}
- G01N 33/507: {Pancreatic cells}
- G01N 33/564: for pre-existing immune complex or autoimmune disease {, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9}
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C12N 2310/11: Antisense
- C12N 2310/14: interfering nucleic acids [NA]
- G01N 2333/775: Apolipopeptides
- G01N 2440/38: addition of carbohydrates, e.g. glycosylation, glycation
- G01N 2500/10: involving cells
- G01N 2800/042: Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
- G01N 2800/50: Determining the risk of developing a disease
- G01N 2800/52: Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present invention provides methods of identifying candidate compounds for the treatment of type I diabetes comprising contacting pancreatic β cells with an amount of apolipoprotein CIII (“apoCIII”) effective to increase intracellular calcium concentration, in the presence of one or more test compounds, and identifying those test compounds that inhibit an apoCIII-induced increase in intracellular calcium concentration in the pancreatic β cells. The present invention also provides methods for treating patients with type I diabetes comprising administering to the patient an amount effective of an inhibitor of apoCIII to reduce apoCIII-induced increase in intracellular calcium concentration in pancreatic β cells.

## Claims

### Claim at position 1

1-5. (canceled)

### Claim 6

(canceled)

### Claim 7

A method for diagnosing a propensity to develop Type 1 diabetes in a subject, comprising:
(a) measuring an amount of sialylated apoCIII in a blood serum sample from the subject;
(b) comparing the amount of sialylated apoCIII measured in step (a) with an amount of sialylated apoCIII in a control blood serum sample; and
(c) diagnosing those subjects with an elevated amount of sialylated apoCIII measured in step (a) relative to the amount of sialylated apoCIII in the control blood serum sample as having Type 1 diabetes.

### Claim 8 (depends on 7)

The method of claim 7, wherein the sialylated apoCIII is mono-sialylated apoCIII.

### Claim 9 (depends on 7)

The method of claim 7, wherein the sialylated apoCIII is di-sialylated apoCIII.

### Claim 10 (depends on 7)

The method of claim 7, wherein the sialylated apoCIII is both mono- and di-sialylated apoCIII.
